Abstract
The commonest cause of peripheral neuropathy is diabetes and pain occurs in approximately 30% of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant difficulties in management, as no treatment to date provides total relief and the side effects of therapy limit dose titration. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments for preventing nerve damage. Furthermore, a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. This review provides an update on the assessment and treatment of painful diabetic neuropathy.
| Original language | English |
|---|---|
| Pages (from-to) | 2969-78 |
| Number of pages | 10 |
| Journal | Expert opinion on pharmacotherapy |
| Volume | 9 |
| Issue number | 17 |
| DOIs | |
| Publication status | Published - Dec 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antidepressive Agents
- Diabetic Neuropathies
- Humans
- Pancreas Transplantation
- Physical Therapy Modalities
- Thioctic Acid
- Journal Article
- Review
Fingerprint
Dive into the research topics of 'Management of painful diabetic neuropathy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver